Sevsury: Withdrawal of the marketing authorisation application



Hutchmed Europe B.V. withdrew its application for a marketing authorisation of Sevsury for the treatment of progressive neuroendocrine tumours.

The company withdrew the application on 1 August 2022.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Sevsury (surufatinib) (PDF/145.36 KB)

    First published: 19/08/2022
    Last updated: 16/11/2022

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • surufatinib
    Active substance
    • surufatinib
    Date of withdrawal
    Company making the application
    Hutchmed Europe B.V.
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating